A phase 1 trial of the PARP inhibitor fuzuloparib in combination with the anti-angiogenic apatinib in recurrent ovarian or triple-negative breast cancer.

被引：0
|
作者：
Li, Huiping
Zhang, Jiayang
Yin, Rutie
Song, Nan
Zhang, Youzhong
Zhang, Yu
Zhang, Keqiang
Pan, Hongming
Wang, Ke
Lou, Ge
Li Guiling
Zhang, Ben
Wang, Quanren
Gao, Yunong
机构：
[1] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Breast Oncol, Minist Educ Beijing, Beijing, Peoples R China
[2] Sichuan Univ, Dept Gynecol & Obstet, West China Univ Hosp 2, Chengdu, Peoples R China
[3] Sichuan Univ, West China Univ Hosp 2, Key Lab Obstet & Gynecol & Pediat Dis & Birth Def, Minist Educ, Chengdu, Peoples R China
[4] Peking Univ Canc Hosp & Inst, Dept Gynecol Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China
[5] Shangdong Univ, Dept Obstet & Gynecol, Qilu Hosp, Shandong, Peoples R China
[6] Cent South Univ, Xiangya Hosp, Med Eth Comm, Changsha, Peoples R China
[7] Hunan Canc Hosp, Gynecol Oncol Ward 5, Changsha, Peoples R China
[8] Zhejiang Univ, Dept Med Oncol, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China
[9] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[10] Harbin Med Univ, Gynecol Ward 1, Canc Hosp, Harbin, Peoples R China
[11] Huazhong Univ Sci & Technol, Union Hosp, Dept Gynecol Oncol, Tongji Med Coll, Wuhan, Peoples R China
[12] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
[13] Beijing Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5539
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [41] PARP1 in triple-negative breast cancer: Expression and therapeutic potential
    Cotter, M. B.
    Pierce, A.
    McGowan, P. M.
    Madden, S. F.
    Flanagan, L.
    Quinn, C.
    Evoy, D.
    Crown, J.
    McDermott, E.
    Duffy, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] Structural Modifications on CORM-3 Lead to Enhanced Anti-angiogenic Properties Against Triple-negative Breast Cancer Cells
    Kourti, Malamati
    Cai, Jun
    Jiang, Wen
    Westwell, Andrew D.
    MEDICINAL CHEMISTRY, 2021, 17 (01) : 40 - 59
  • [43] Preliminary safety and efficacy results of camrelizumab in combination with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer: A phase II trial
    Liu, Jieqiong
    Tian, Zhenluan
    Wang, Ying
    Lin, Ying
    Li, Hengyu
    CANCER RESEARCH, 2022, 82 (04)
  • [44] A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer.
    Ling, Huichung Tina
    Muggia, Franco
    Speyer, James L.
    Curtin, John Patrick
    Blank, Stephanie V.
    Boyd, Leslie R.
    Pothuri, Bhavana
    Li, Xiaochun
    Goldberg, Judith D.
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Synergistic chemosensitivity of triple-negative breast cancer cell lines to a PARP inhibitor, cisplatin and gemcitabine
    Hastak, Kedar
    Alli, Elizabeth
    Ford, James
    CANCER RESEARCH, 2009, 69
  • [46] PRMT5 inhibitor synergizes with PARP inhibitors in triple-negative breast cancer cells
    Suresh, Samyuktha
    McPherson, Lisa A.
    Ford, James M.
    CANCER RESEARCH, 2023, 84 (06)
  • [47] A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.
    Mitri, Zahi Ibrahim
    Vuky, Jacqueline
    Kemmer, Kathleen A.
    Savin, Michael A.
    Parmar, Swapnil
    Kolodzie, Annette Kolodzie
    Johnson, Brett
    Williams-Belizaire, Rochelle
    Gray, Joe W.
    Mills, Gordon B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretrnted patients with metastatic triple-negative breast cancer
    Hu, Xichun
    Zhang, Jian
    Xu, Binghe
    Jiang, Zefei
    Ragaz, Joseph
    Tong, Zhongsheng
    Zhang, Qingyuan
    Wang, Xiaojia
    Feng, Jifeng
    Pang, Danmei
    Fan, Minhao
    Li, Jin
    Wang, Biyun
    Wang, Zhonghua
    Zhang, Qunling
    Sun, Si
    Liao, Chunmei
    INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (08) : 1961 - 1969
  • [49] A Biomimetic Collagen Derived Peptide Exhibits Anti-Angiogenic Activity in Triple Negative Breast Cancer
    Rosca, Elena V.
    Penet, Marie-France
    Mori, Noriko
    Koskimaki, Jacob E.
    Lee, Esak
    Pandey, Niranjan B.
    Bhujwalla, Zaver M.
    Popel, Aleksander S.
    PLOS ONE, 2014, 9 (11):
  • [50] Preclinical efficacy of dasatinib in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer xenograft model
    Sun, Y.
    Lin, X.
    Carlson, Jh
    De, P.
    Dey, N.
    Williams, C.
    Leyland-Jones, B.
    CANCER RESEARCH, 2017, 77
12345